Table 6.
Characteristics of the included studies which employed PSMA radioligands in hepatocellular carcinoma.
| First Author and Year | Type | Country | N. Patients | Tracer | Clinical Setting (N. Patients) |
Analysed Lesions | Comparator |
|---|---|---|---|---|---|---|---|
| Kesler 2019 [64] | Prospective | Israel | 7 | 68Ga-PSMA-11 (I) | 6 staging 1 restaging after TACE |
37 |
18F-FDG PET/CT CT MRI |
| Kunikowska 2021 [65] | Prospective | Poland | 15 | 68Ga-PSMA-11 (I) | 10 staging, 4 restaging after TACE, 1 restaging after hemiepatectomy and TACE | 44 | CT MRI |
| Gündoğan 2021 [66] | Prospective | Turkey | 14 | 68Ga-PSMA-11 (I) | 12 staging 1 restaging after TACE, 1 restaging after radiofrequency ablation + TACE. |
61 |
18F-FDG PET/CT MRI |
| Hirmas 2021 [67] | Retrospective | Germany | 40 | 68Ga-PSMA-11 (I) | 27 Staging 13 restaging after local or systemic treatment. |
142 | CT |
| Thompson 2022 [68] | Prospective | USA | 31 | 68Ga-PSMA-11 (I) | Staging | 39 | MRI |
PET: positron emission tomography, CT: computed tomography, MRI: magnetic resonance imaging, PSMA: prostate-specific membrane antigen, DCFPyL: piflufolastat, FDG: fluorodeoxyglucose, TACE: transarterial chemo-embolization, TARE: transarterial radio-embolization, I: imaging.